We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...
Shares of Abbott Laboratories and Reckitt Benckiser fell Friday after a judge ruled a new trial could be heard involving a case on their infant formula products that had already seen a ruling in their ...
Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...
8 小时
GlobalData on MSNReckitt’s Mead Johnson, Abbott to face new trial in US infant-formula caseReckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over ...
Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.
根据提交给证券交易委员会的文件显示,Abbott Laboratories(NYSE:ABT)执行副总裁Louis H. Morrone最近进行了一系列股票交易。3月3日,Morrone以每股138.17美元的价格出售了1,111股Abbott ...
Abbott Laboratories and Reckitt Benckiser Group Plc shares fell as a judge ordered a new trial after rejecting a verdict that ...
Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary Mead Johnson not responsible for a ...
Abbott将在临床试验的多个方面提供支持,包括规划、试验点选择以及分享其HeartMate 3™的使用经验。在LVAD市场中,Abbott的HeartMate 3™是目前美国唯一可用的设备,该市场在2023年估值为USD 11亿,预计到2032年将达到USD 24亿。
Key Takeaways Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could ...
Missouri 22nd Judicial Circuit Court Judge Michael Noble granted the plaintiff's motion for a new trial on Thursday, citing ...
The ruling overturned a previous verdict related to an infant formula case and has implications for both Abbott and Reckitt, ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果